PMID- 31207081
OWN - NLM
STAT- MEDLINE
DCOM- 20200814
LR  - 20210311
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 23
IP  - 8
DP  - 2019 Aug
TI  - Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular 
      carcinoma progression by sponging miR-133a to regulate IGF-1R expression.
PG  - 5154-5164
LID - 10.1111/jcmm.14384 [doi]
AB  - Long non-coding RNA (lncRNA) deleted in lymphocytic leukaemia 1 (DLEU1) was 
      reported to be involved in the occurrence and development of multiple cancers. 
      However, the exact expression, biological function and underlying mechanism of 
      DLEU1 in hepatocellular carcinoma (HCC) remain unclear. In this study, real-time 
      quantitative polymerase chain reaction (qRT-PCR) in HCC tissues and cell lines 
      revealed that DLEU1 expression was up-regulated, and the increased DLEU1 was 
      closely associated with advanced tumour-node-metastasis stage, vascular 
      metastasis and poor overall survival. Function experiments showed that knockdown 
      of DLEU1 significantly inhibited HCC cell proliferation, colony formation, 
      migration and invasion, and suppressed epithelial to mesenchymal transition (EMT) 
      process via increasing the expression of E-cadherin and decreasing the expression 
      of N-cadherin and Vimentin. Luciferase reporter gene assay and RNA 
      immunoprecipitation (RIP) assay demonstrated that DLEU1 could sponge miR-133a. 
      Moreover, miR-133a inhibition significantly reversed the suppression effects of 
      DLEU1 knockdown on HCC cells. Besides, we found that silenced DLEU1 significantly 
      decreased insulin-like growth factor 1 receptor (IGF-1R) expression (a target of 
      miR-133a) and its downstream signal PI3K/AKT pathway in HCC cells, while miR-133a 
      inhibitor partially reversed this trend. Furthermore, DLEU1 knockdown impaired 
      tumour growth in vivo by regulating miR-133a/IGF-1R axis. Collectively, these 
      findings indicate that DLEU1 promoted HCC progression by sponging miR-133a to 
      regulate IGF-1R expression. Deleted in lymphocytic leukaemia 1/miR-133a/IGF-1R 
      axis may be a novel target for treatment of HCC.
CI  - (c) 2019 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin 
      University, Changchun, P.R. China.
FAU - Liu, Songyang
AU  - Liu S
AD  - Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin 
      University, Changchun, P.R. China.
FAU - Liu, Kai
AU  - Liu K
AD  - Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin 
      University, Changchun, P.R. China.
FAU - Liu, Yahui
AU  - Liu Y
AUID- ORCID: 0000-0003-4698-5370
AD  - Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin 
      University, Changchun, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190617
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (DLEU1 lncRNA, human)
RN  - 0 (IGF1R protein, human)
RN  - 0 (MIRN133 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Carcinoma, Hepatocellular/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Liver Neoplasms/*genetics/pathology
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - RNA, Long Noncoding
MH  - Receptor, IGF Type 1/*genetics
MH  - Signal Transduction/genetics
MH  - Tumor Suppressor Proteins/*genetics
PMC - PMC6653240
OTO - NOTNLM
OT  - DLEU1
OT  - IGF-1R
OT  - LncRNAs
OT  - PI3K/AKT
OT  - hepatocellular carcinoma
OT  - miR-133a
COIS- The authors declare that they have no conflict of interest.
EDAT- 2019/06/18 06:00
MHDA- 2020/08/15 06:00
PMCR- 2019/08/01
CRDT- 2019/06/18 06:00
PHST- 2018/09/16 00:00 [received]
PHST- 2019/03/11 00:00 [revised]
PHST- 2019/04/19 00:00 [accepted]
PHST- 2019/06/18 06:00 [pubmed]
PHST- 2020/08/15 06:00 [medline]
PHST- 2019/06/18 06:00 [entrez]
PHST- 2019/08/01 00:00 [pmc-release]
AID - JCMM14384 [pii]
AID - 10.1111/jcmm.14384 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2019 Aug;23(8):5154-5164. doi: 10.1111/jcmm.14384. Epub 2019 Jun 
      17.